Development of an immune-related gene prognostic risk model and identification of an immune infiltration signature in the tumor microenvironment of colon cancer.
Colon cancer
Immune gene
Prognosis
Risk model
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
08 Mar 2023
08 Mar 2023
Historique:
received:
20
06
2022
accepted:
15
02
2023
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Colon cancer is a common and highly malignant tumor. Its incidence is increasing rapidly with poor prognosis. At present, immunotherapy is a rapidly developing treatment for colon cancer. The aim of this study was to construct a prognostic risk model based on immune genes for early diagnosis and accurate prognostic prediction of colon cancer. Transcriptome data and clinical data were downloaded from the cancer Genome Atlas database. Immunity genes were obtained from ImmPort database. The differentially expressed transcription factors (TFs) were obtained from Cistrome database. Differentially expressed (DE) immune genes were identified in 473 cases of colon cancer and 41 cases of normal adjacent tissues. An immune-related prognostic model of colon cancer was established and its clinical applicability was verified. Among 318 tumor-related transcription factors, differentially expressed transcription factors were finally obtained, and a regulatory network was constructed according to the up-down regulatory relationship. A total of 477 DE immune genes (180 up-regulated and 297 down-regulated) were detected. We developed and validated twelve immune gene models for colon cancer, including SLC10A2, FABP4, FGF2, CCL28, IGKV1-6, IGLV6-57, ESM1, UCN, UTS2, VIP, IL1RL2, NGFR. The model was proved to be an independent prognostic variable with good prognostic ability. A total of 68 DE TFs (40 up-regulated and 23 down-regulated) were obtained. The regulation network between TF and immune genes was plotted by using TF as source node and immune genes as target node. In addition, Macrophage, Myeloid Dendritic cell and CD4 We developed and validated twelve immune gene models for colon cancer, including SLC10A2, FABP4, FGF2, CCL28, IGKV1-6, IGLV6-57, ESM1, UCN, UTS2, VIP, IL1RL2, NGFR. This model can be used as a tool variable to predict the prognosis of colon cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Colon cancer is a common and highly malignant tumor. Its incidence is increasing rapidly with poor prognosis. At present, immunotherapy is a rapidly developing treatment for colon cancer. The aim of this study was to construct a prognostic risk model based on immune genes for early diagnosis and accurate prognostic prediction of colon cancer.
METHODS
METHODS
Transcriptome data and clinical data were downloaded from the cancer Genome Atlas database. Immunity genes were obtained from ImmPort database. The differentially expressed transcription factors (TFs) were obtained from Cistrome database. Differentially expressed (DE) immune genes were identified in 473 cases of colon cancer and 41 cases of normal adjacent tissues. An immune-related prognostic model of colon cancer was established and its clinical applicability was verified. Among 318 tumor-related transcription factors, differentially expressed transcription factors were finally obtained, and a regulatory network was constructed according to the up-down regulatory relationship.
RESULTS
RESULTS
A total of 477 DE immune genes (180 up-regulated and 297 down-regulated) were detected. We developed and validated twelve immune gene models for colon cancer, including SLC10A2, FABP4, FGF2, CCL28, IGKV1-6, IGLV6-57, ESM1, UCN, UTS2, VIP, IL1RL2, NGFR. The model was proved to be an independent prognostic variable with good prognostic ability. A total of 68 DE TFs (40 up-regulated and 23 down-regulated) were obtained. The regulation network between TF and immune genes was plotted by using TF as source node and immune genes as target node. In addition, Macrophage, Myeloid Dendritic cell and CD4
CONCLUSION
CONCLUSIONS
We developed and validated twelve immune gene models for colon cancer, including SLC10A2, FABP4, FGF2, CCL28, IGKV1-6, IGLV6-57, ESM1, UCN, UTS2, VIP, IL1RL2, NGFR. This model can be used as a tool variable to predict the prognosis of colon cancer.
Identifiants
pubmed: 36890467
doi: 10.1186/s12876-023-02679-6
pii: 10.1186/s12876-023-02679-6
pmc: PMC9996977
doi:
Substances chimiques
Fibroblast Growth Factor 2
103107-01-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Subventions
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Organisme : National Natural Science Foundation of China
ID : 82170525
Informations de copyright
© 2023. The Author(s).
Références
Cancer Immunol Immunother. 2022 Nov;71(11):2619-2629
pubmed: 35316367
Genome Biol. 2011 Aug 22;12(8):R83
pubmed: 21859476
EMBO J. 2021 Feb 15;40(4):e105450
pubmed: 33347625
Prostate. 2019 Feb;79(3):288-294
pubmed: 30411388
Cancer Cell Int. 2020 Oct 19;20:512
pubmed: 33088219
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Cancer Microenviron. 2009 Sep 25;2(1):69-80
pubmed: 19779850
Sci Data. 2018 Feb 27;5:180015
pubmed: 29485622
Cancer Res. 2012 Apr 1;72(7):1705-16
pubmed: 22396497
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Curr Oncol Rep. 2019 Jan 18;21(1):3
pubmed: 30659375
Expert Rev Anticancer Ther. 2021 Oct;21(10):1161-1170
pubmed: 34319826
Prostate. 2009 May 15;69(7):774-86
pubmed: 19189304
Int J Mol Sci. 2021 Nov 25;22(23):
pubmed: 34884543
Eur J Cancer. 2020 Oct;138:182-188
pubmed: 32892120
Carcinogenesis. 2015 Oct;36(10):1193-200
pubmed: 26210740
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Oncol Rep. 2012 Nov;28(5):1701-8
pubmed: 22948784
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Semin Immunopathol. 2017 Apr;39(3):295-305
pubmed: 27787613
Expert Rev Mol Diagn. 2022 Feb;22(2):223-231
pubmed: 34904499
Biomed Pharmacother. 2019 Feb;110:312-318
pubmed: 30522017
J Gastroenterol. 2002;37(5):336-44
pubmed: 12051532
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
Cancer Res. 2020 May 15;80(10):2004-2016
pubmed: 32156780
Int Immunopharmacol. 2020 Dec;89(Pt A):107041
pubmed: 33045561
Semin Cancer Biol. 2022 Nov;86(Pt 3):400-407
pubmed: 35183412
Gastroenterol Rep (Oxf). 2020 Sep 14;8(5):381-389
pubmed: 33163194
Biomed Pharmacother. 2018 Dec;108:766-773
pubmed: 30248545
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269922
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Compr Canc Netw. 2020 Sep;18(9):1230-1237
pubmed: 32886900
Oncogene. 2021 Mar;40(12):2165-2181
pubmed: 33627781
Immunol Invest. 2018 Oct;47(7):643-653
pubmed: 29924680
Cancer Immunol Immunother. 2013 Jun;62(6):989-97
pubmed: 23591979
Cancer Res. 2011 Aug 1;71(15):5123-33
pubmed: 21697281
Front Immunol. 2018 Sep 11;9:2076
pubmed: 30258445
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
Cancer Res. 2020 Dec 1;80(23):5317-5329
pubmed: 33023944
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52
pubmed: 20176268
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Front Mol Biosci. 2020 Nov 27;7:604252
pubmed: 33330631
Int J Biochem Cell Biol. 2014 Aug;53:108-14
pubmed: 24819541
Expert Rev Mol Diagn. 2019 Apr;19(4):313-324
pubmed: 30907673
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406504
Semin Cancer Biol. 2018 Oct;52(Pt 2):189-197
pubmed: 29501787
Cancer Sci. 2019 Jan;110(1):235-244
pubmed: 30390393
PLoS One. 2012;7(4):e35561
pubmed: 22558167
Vaccines (Basel). 2017 Feb 27;5(1):
pubmed: 28264447
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Mol Genet Genomic Med. 2021 Aug;9(8):e1740
pubmed: 34192422
PLoS One. 2014 Apr 03;9(4):e93756
pubmed: 24699879
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
Bioinformatics. 2017 Apr 1;33(7):1101-1103
pubmed: 28057685
Annu Rev Genet. 2007;41:107-20
pubmed: 17576170
Cell Signal. 2014 May;26(5):1125-34
pubmed: 24518041